Lesson plan

Sciensus

Sciensus Pharma Services Limited is a global life sciences business established in 1992 by founder and former chairman Charles Walsh based in London. The company supplies a wide range of specialist medications and patient support programmes for chronic, cancer and rare disease patients, with around 1,600 employees dealing with more than 230,000 patients a year. It works with every NHS trust in the UK. In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries. In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market. The company's name was changed in 2022 from "Healthcare at Home LTD" to "Sciensus Pharma Limited", using only "Sciensus" to refer to themselves from then on. In July 2023, 1 patient died and 3 were hospitalised after being administered unlicensed versions of cabazitaxel chemotherapy provided by Sciensus. This follows reports in May 2023 of complaints of poor service and delays raised about the company, sparking a possible CQC review. This resulted in "partial suspension" of its licence by the Medicines and Healthcare products Regulatory Agency (MHRA).

Back to article

Article summary

Sciensus Pharma Services Limited is a global life sciences business established in 1992 by founder and former chairman Charles Walsh based in London. The company supplies a wide range of specialist medications and patient support programmes for chronic, cancer and rare disease patients, with around 1,600 employees dealing with more than 230,000 patients a year. It works with every NHS trust in the UK. In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries. In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market. The company's name was changed in 2022 from "Healthcare at Home LTD" to "Sciensus Pharma Limited", using only "Sciensus" to refer to themselves from then on. In July 2023, 1 patient died and 3 were hospitalised after being administered unlicensed versions of cabazitaxel chemotherapy provided by Sciensus. This follows reports in May 2023 of complaints of poor service and delays raised about the company, sparking a possible CQC review. This resulted in "partial suspension" of its licence by the Medicines and Healthcare products Regulatory Agency (MHRA).

Key claims

  1. date of establishment: 1992 — source: Wikipedia, revision 1359472545, retrieved 2026-10-20 · confidence 0.95
  2. employees: 1,600 employees — source: Wikipedia, revision 1359472545, retrieved 2026-10-20 · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the date of establishment is "1992". What evidence would count against this claim?
  3. The record states that the employees is "1,600 employees". What evidence would count against this claim?
  4. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  5. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia, “Sciensus”, revision 1359472545, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1359472545

Key claims and bibliography are generated from the same tracked claims and sources as the article page.